E

Erytech Pharma SA
PAR:ERYP

Watchlist Manager
Erytech Pharma SA
PAR:ERYP
Watchlist
Price: 0.801 EUR 0.25% Market Closed
Market Cap: 27.3m EUR

Erytech Pharma SA
Investor Relations

ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 196 full-time employees. The company went IPO on 2013-05-07. The firm offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer. The firm's technology is based on the use of human red blood cells (RBCs) to improve the pharmacokinetic (PK) and pharmacodynamic (PD) properties of therapeutic enzymes, for instance asparaginase. The enzyme can destroy asparagine and deprive cancer cells of an important nutrient for these cells, resulting in their death.

Show more
Loading
ERYP
DAX Index
1Y 3Y 5Y 10Y 15Y 20Y
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q1 2023
Call Date
May 10, 2023
Q1 2023 Earnings Call
No Analysis Available

This earnings call has not been analyzed yet.

If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.

Request Earnings Call Analysis
Earnings Call Recording
Open Transcript
Other Earnings Calls

Management

Contacts

Address
AUVERGNE-RHONE-ALPES
Lyon
60 avenue Rockefeller, Batiment Adenine
Contacts
+33478744438.0
erytech.com
sparklesyt

See Also

Summary
ERYP intrinsic value, competitors valuation, and company profile.
DCF Valuation
ERYP stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ERYP stock valuation using valuation multiples.
Wall Street Estimates
ERYP price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ERYP stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Back to Top
ALPHA SPREAD
Follow us
Join more than 308,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.